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Objective: To document Toxoplasma gondii (T. gondii) antibody status in patients with
liver disease, blood samples were taken from 180 hepatic patients and 180 healthy
controls.
Methods: Toxoplasma IgG antibody was detected using enzyme-linked immunosorbent
assay and histopathological assessment of liver biopsy METAVIR score was applied.
Results: Anti-T. gondii IgG antibodies were found in 32.8% of patients and in 22.2% of
controls (P = 0.02). Toxoplasma seropositivity was signiﬁcantly associated with
lymphadenopathy, history of blood transfusion and reﬂex impairment in patients. Chronic
hepatitis C virus (HCV) and chronic HCV-related cirrhosis groups compared to chronic
HBV and chronic HBV-related cirrhosis groups expressed signiﬁcantly higher prevalence
of T. gondii seropositivity (odds ratio (OR) = 4; 95% conﬁdence interval (CI): 1.3–12.6;
P = 0.013, OR = 4.8; 95% CI: 1.5–14.9; P = 0.006, respectively). Within the chronic
HCV group, T. gondii seropositivity signiﬁcantly associated disease evolution as regards
to METAVIR histopathological system for ﬁbrosis and inﬂammation (OR = 19.4; 95%
CI: 2.3–165.2; P = 0.0008, OR = 0.29; 95% CI: 0.1–0.8; P = 0.01, respectively). Al-
bumin, international normalized ratio (INR) and platelets count were the laboratory pa-
rameters signiﬁcantly altered in Toxoplasma-positive chronic HCV patients (P = 0.001,
0.03, 0.04, respectively). Child-Pugh scoring for cirrhosis in chronic HCV group placed
the majority of seropositive patient in class C with signiﬁcant statistical difference
compared to Child A reference group (OR = 0.08; 95% CI: 0.01–0.5; P = 0.003).
Conclusions: Toxoplasma seropositivity was high in patients with cirrhosis and asso-
ciated higher grades of inﬂammation and necrosis signifying disease evolution, sug-
gesting that cirrhotic patients may thus form a risk group for toxoplasmosis.1. Introduction
Toxoplasmosis is a parasitic zoonosis with the highest human
incidence [1]. Seroprevalence of Toxoplasma infection among
immunocompromised patients is high and reactivation of latent
infections in them can be life-threatening [2]. During chronic
toxoplasmosis, both CD4+ and CD8+ T lymphocytes are
required to prevent reactivation of toxoplasmosis. Thus,
depletion of T cells in the setting of chronic infection as indepressed cellular immunity states, leads to reactivation of latent
infection [3]. Cirrhosis is considered an immunocompromised
state that leads to a variety of infections, which then account for
an approximate 30% mortality [4].
Hepatic involvement in toxoplasmosis does exist but it may go
unnoticed as infection spreads to the liver early in course of
infection and may not induce laboratory or clinical alterations [5].
Granulomatous hepatitis [5], hepatomegaly, abnormal liver
function tests [6], cholestatic jaundice [7], cirrhosis [8] as well as
liver dysfunction in liver and kidney transplant recipients [9] are
the usually reported consequences. Hepatitis in Toxoplasma
infection varies between 11% and 89% depending on the
virulence of the strain [10].
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are
hepatotropic viruses affecting about 600 million individualsopen access article under the CC BY-NC-ND
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hepatocellular carcinoma are usual consequences of chronic
infections resulting in 1 million deaths per year [11].
Toxoplasma and hepatitis viruses are intracellular pathogens
that both stimulate polarised immune responses involving
Th1 cytokine proﬁles (pro-inﬂammatory mediators) such as
IL-12, IFN-g and nitric oxide [12]. In developing countries,
co-infection by more than one pathogen is widespread and it
remains an underestimated risk factor for infection although it
can play a critical role in the infection outcome via effects on
the host immune response or by inducing changes in host
physiology [13].
Globally, the prevalence of latent Toxoplasma infection
among patients with hepatitis B and C viruses as well as
cirrhotic patients has not been extensively investigated, and the
effect of co-infections with these pathogens on the progression
of liver disease needs to be clariﬁed especially in Egypt where
all of these pathogens are reported with high prevalence rates.
The paucity of information motivated us to undertake this study
to determine the prevalence of latent Toxoplasma infection
among chronic viral hepatitis as well as cirrhotic patients
compared to controls not complaining of liver disease and to
explore the effects of co-infection on the course of liver disease
within these patient groups.
2. Materials and methods
2.1. Participants
A comparative cross-sectional study was performed at Man-
souraUniversity Hospital, Egypt, during the periodMay 2013 and
January 2014. One hundred and eighty patients with chronic HCV
or chronic HBV, who attended the Tropical Medicine Department
[67 females and 113males, with mean age ±SD of (50.14 ± 12.60)
years], participated in the study. Exclusion criteria included pa-
tients with schistosomiasis, heart failure, diabetes mellitus, hy-
pertension, hyperlipidemia, peripheral vascular disease,
hematological and neoplastic disorders. None of patients had
received anticoagulant medications, non-steroidal anti-inﬂam-
matory drugs or oral contraceptive drugs before hospital admis-
sion. Patient groups were matched regarding age, gender and
residence with 180 healthy controls [70 females and 110 males
with mean age ± SD of (48.0 ± 7.5) years].
Patients were divided into 4 groups: Group I;: chronic HCV
(n = 75 patients); Group II: chronic HCV-related cirrhosis
(n = 45 patients); Group III: chronic HBV (n = 36 patients);
Group IV: chronic HBV-related cirrhosis (n = 24 patients).
2.2. Ethical aspects
This study was approved by the Ethical Committee of
Mansoura University. All participants were acquainted with the
study and gave informed consent to participate in it after fully
explaining the aim of the study to them. The study was con-
ducted in accordance with the guidelines of the Helsinki
Declaration.
2.3. Laboratory tests
Five mL of venous blood were withdrawn from patients and
control participants and were divided into 3 aliquots: the ﬁrstaliquot was used for liver function tests [ALT, AST, ALP, serum
albumin, bilirubin, international normalized ratio (INR)], CBC
and indirect haemagglutination test (IHA) for schistosomiasis to
detect prior schistosomal infection, while the second was used
for serum HBV surface antigen (HBs Ag) and HCV detection by
PCR, and the third was analyzed for anti-Toxoplasma IgG
antibody detection, using commercial Toxoplama IgG detection
kit (DS-EIA-Anti-Toxo-G-Fast, DSI, Italy).
For Toxoplasma antibody testing, blood samples were pro-
cessed immediately by centrifugation at 4000 rpm for 5 min
after which they were kept at −20 C until analysis. Anti-
Toxoplasma gondii (T. gondii) IgG antibody levels were
expressed as international units (IU)/mL, and a result greater
than 15.95 IU/mL was considered positive. All tests were per-
formed following the instructions of the manufacturer.
2.4. Histopathology of percutaneous ultrasound guided
liver biopsy
Liver biopsies were analysed after parafﬁn embedding. Five
mm sections were obtained from chronic HCV group, for he-
matoxylin and eosin (H&E) and Masson's trichrome staining.
Each liver tissue sample was diagnosed on the basis of the
presence of at least 10 complete portal tracts, which has long
been considered the ‘gold standard’ to determine liver histol-
ogy, disease activity and liver ﬁbrosis [14]. The degree of
histologic hepatic ﬁbrosis and inﬂammation was scored using
the METAVIR scoring system [15]. Based on the degree of
lymphocyte inﬁltration and hepatocyte necrosis, the level of
inﬂammation was classiﬁed from A0 to A3, with a higher
score indicating more severe inﬂammation. Fibrosis was
graded from F0 to F4 as follows: F0: no ﬁbrosis, F1: portal
ﬁbrosis without septa, F2: portal ﬁbrosis with rare septa, F3:
numerous septa without cirrhosis, and F4: cirrhosis. Steatosis
was quantiﬁed as the percentage of hepatocytes that
contained fat droplets and classiﬁed into three groups: <5%,
5%–30% and >30% [16]. Liver biopsy was assessed by a
pathologist blinded to clinical and laboratory data. All
demographic and laboratory data were collected at the time
of the liver biopsy.
2.5. Statistical analysis
To test for normal distribution, frequency of data was plotted
against normal distribution curve. All data were parametric as
most of the quantitative data showed normal distribution using
Kolmogrov–smirnov test to test for normality. Frequency, mean,
standard deviation were used to describe data. Chi-square test
was used to test for association between Toxoplasma infection
and sociodemographic and clinical characteristics. A student's t-
test was used to compare the means between groups. A P
value < 0.05 was considered statistically signiﬁcant. These tests
were run on an IBM compatible personal computer using the
Statistical Package for Social Scientists for windows Ver. 20
(SPSS Inc., Chicago, IL, USA).
3. Results
Anti-T. gondii IgG antibodies were found in 59 (32.8%) of
180 patients and in 40 (22.2%) of 180 controls (P = 0.02). Of the
anti-T. gondii IgG positive patients, 23 (39%) had IgG levels
Table 1
Demographic and clinical data of T. gondii seropositive against seronegative patients.
Characteristic Seropositives (n = 59) [n (%)] Seronegatives (n = 121) [n (%)] OR (95% CI) c2 P
Gender
Male (n = 113) 36 (61.0) 77 (63.6) 0.9 (0.7–1.7) 0.12 0.73
Female (n = 67) 23 (38.9) 44 (36.4)
Age groups (years)
30 (n = 20) 10 (16.9) 10 (8.3) 2.3 (0.8–6.4) 2.30 0.10
31-50 (n = 90) 28 (47.5) 62 (51.2) 1.1 (0.5–2.0) 0.02 0.88
50 (n = 70, r**) 21 (35.5) 49 (40.5)
Residence area
Urban (n = 120) 43 (72.9) 77 (63.6) 1.5 (0.8–3.0) 1.50 0.22
Rural (n = 60) 16 (27.1) 44 (36.4)
Socio-economic level
Low (n = 131) 41 (69.5) 90 (74.4) 0.8 (0.4–1.6) 0.48 0.49
Medium (n = 49) 18 (30.5) 31 (25.6)
Educational level
Illiterate (n = 12) 6 (10.2) 6 (4.9) 1.9 (0.45–7.80) 0.76 0.40
Pre-high (n = 145) 45 (76.2) 100 (82.6) 1.2 (0.47–3.00) 0.13 0.70
High (n = 23, r**) 8 (13.6) 15 (12.4)
Occupation
Jobless (n = 63) 17 (28.8) 46 (38.0) 0.7 (0.3–1.3) 1.50 0.24
Worker (n = 117) 42 (71.2) 75 (62.0.)
Lymphadenopathy
Yes (n = 46) 22 (37.3) 24 (19.8) 2.4 (1.2–4.8) 6.40 0.01*
No (n = 134) 37 (62.7) 97 (80.2)
Blood transfusion
Yes (n = 67) 33 (55.9) 34 (28.1) 3.2 (1.7–6.2) 13.10 0.0003*
No (n = 113) 26 (44.1) 87 (71.9)
Reﬂex impairmenta,b
Yes (n = 36) 21 (35.6) 15 (12.4) 3.9 (1.8–8.3) 13.30 0.0003*
No (n = 144) 38 (64.4) 106 (87.6)
Visual impairmentb
Yes (n = 45) 18 (30.5) 27 (22.3) 1.5 (0.76–3.00) 1.40 0.23
No (n = 135) 41 (69.5) 94 (77.7)
*Statistical signiﬁcance at P < 0.05, **reference group.
a Biceps, triceps, knee jerk, ankle jerk and Babinski's sign.
b Testing was done according to the regulation of ministry of health prior to interferon therapy.
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and 99 IU/mL. In comparison 18 (45%) of the anti-T. gondii IgG
positive controls showed IgG levels higher than 100 IU/mL, and
22 (55%) expressed levels between 16 and 99 IU/mL. Anti-T.
gondii IgG levels were comparable (P = 0.50) among patients
and controls (data not shown).Table 2
Seroprevalence of T. gondii infection in patient groups.
Patient
category
Seropositives
[n (%)]
Seronegatives
[n (%)]
OR
(95% CI)
c2 P
Chronic
HCV
(n = 75)
25 (33.3) 50 (66.7) 4.0
(1.3–12.6)
6.2 0.013*
Chronic
HBV
(n = 36)
4 (11.1) 32 (88.9)
Chronic
HCV-
related
cirrhosis
(n = 45)
25 (55.6) 20 (44.4) 4.8
(1.5–14.9)
7.7 0.006*
Chronic
HBV-
related
cirrhosis
(n = 24)
5 (20.8) 19 (79.2)
*Statistical signiﬁcance at P < 0.05.As Table 1 implies, none of the sociodemographic charac-
teristics showed statistically signiﬁcant association to Toxo-
plasma seropositivity in patient groups. Among clinical data,
lymphadenopathy, history of blood transfusion and reﬂex
impairment were signiﬁcantly higher in seropositive patients
[odds ratio (OR) = 2.4; 95% conﬁdence interval (CI): 1.2–4.8;
P = 0.01, OR = 3.2; 95% CI: 1.7–6.2; P = 0.0003, OR = 3.9;
95% CI: 1.8–8.3; P = 0.0003, respectively].
Table 2 shows the statistically signiﬁcant difference be-
tween seroprevalence of anti-T. gondii IgG in chronic HCV and
chronic HCV-related cirrhosis groups compared to chronic
HBV and chronic HBV-related cirrhosis groups (OR = 4.0;
95% CI: 1.3–12.6; P = 0.013, OR = 4.8; 95% CI: 1.5–14.9;
P = 0.006, respectively). Interestingly, within the chronic HCV
group, a signiﬁcant difference in seroprevalence of T. gondii as
regards to METAVIR scoring was observed (Table 3).
T. gondii infection was positive in 68% (17/25) of patients with
late ﬁbrosis (F3 + F4) with signiﬁcant statistical difference
compared to F0 reference group (OR = 19.40; 95% CI: 2.3–
165.2; P = 0.0008), while positivity was 28% in early ﬁbrosis
cases (F1 + F2). Similarly, most of T. gondii positive cases
(68%) were METAVIR activity (A2-A3) compared to 32% for
METAVIR activity (A0-A1) with statistical signiﬁcance
(OR = 0.29; 95% CI: 0.1–0.8; P = 0.01). In accordance, within
the same METAVIR scoring for ﬁbrosis, higher degree and
extent of necrosis marked liver biopsies of Toxoplasma infec-
ted (Figures 1B and 2B) compared to Toxoplasma uninfected
chronic HCV patients (Figures 1A and 2A).
Table 3
Liver biopsy METAVIR scores in chronic HCV patients according to
Toxoplasma serostatus.
Liver
biopsy
Seropositives
(n = 25)
[n (%)]
Seronegatives
(n = 50)
[n (%)]
OR
(95% CI)
c2 P
Pathology scores
F0 (r**) 1 (4%) 16 (32%)
Early
ﬁbrosis
(F1 + F2)
7 (28%) 20 (40%) 5.0
(0.6–50.3)
2.8 0.09
Late
ﬁbrosis
(F3 + F4)
17 (68%) 14 (28%) 19.4
(2.3–165.2)
11.2 0.0008*
Activity scores
A0- A1 8 (32%) 31 (62%) 0.29
(0.1–0.8)
6.0 0.01*
A2- A3 17 (68%) 19 (38%)
*Statistical signiﬁcance at P < 0.05, **reference group.
Figure 1. Liver biopsy with METAVIR ﬁbrosis score 1 of (A) chronic
HCV-Toxoplasma seronegative patient showing portal lymphocytic inﬁl-
trate with mild piece meal necrosis and no lobular necrosis (activity
score 1); (B) chronic HCV-Toxoplasma seropositive patient showing portal
lymphocytic inﬁltrate with moderate piece meal necrosis and mild lobular
necrosis (activity score 2).
H & E ×100.
Figure 2. Liver biopsy with METAVIR ﬁbrosis score 2 of (A) chronic
HCV-Toxoplasma seronegative patient showing portal lymphocytic inﬁl-
trate with moderate piece meal necrosis and mild lobular necrosis (activity
score 2); (B) chronic HCV-Toxoplasma seropositive patient showing portal
lymphocytic inﬁltrate with moderate piece meal necrosis and moderate
lobular necrosis (activity score 3).
H & E ×100.
Table 4
Laboratory parameters in chronic HCV patients according to Toxoplasma
serostatus.
Parameter Seropositives Seronegatives P
Albumin (g/dL) 3.34 ± 0.44 3.81 ± 0.62 0.001*
Bilirubin (mg/dL) 1.50 ± 0.90 1.37 ± 0.80 0.500
ALT (IU/mL) 51.65 ± 12.00 55.20 ± 15.00 0.300
AST (IU/mL) 69.85 ± 21.30 64.81 ± 19.30 0.300
ALP KU 15.03 ± 5.10 12.80 ± 3.80 0.060
INR 1.16 ± 0.16 1.09 ± 0.11 0.030*
Hb (g/dL) 11.12 ± 1.98 11.67 ± 2.10 0.200
WBCs/109/L 4.70 ± 1.81 4.53 ± 1.64 0.600
Platelet/109/L 129.87 ± 25.00 141.71 ± 22.90 0.040*
HCV PCR × 104 201.34 ± 33.57 196.37 ± 31.35 0.500
ALT: alanine aminotransaminase, AST: aspartate aminotransferase,
ALP: alkaline phosphatase, KU: king unit, INR: international normal-
ized ratio, Hb: hemoglobin, WBC: white blood cell, HCV: Hepatitis C
virus, PCR: Polymerase chain reaction.
*Statistical signiﬁcance at P < 0.05.
Table 5
Child-Pugh score of chronic HCV-related cirrhosis group patients ac-
cording to Toxoplasma serostatus.
Child-
Pugh
score
Seropositives
(n = 25)
[n (%)]
Seronegatives
(n = 20)
[n (%)]
OR
(95% CI)
c2 P
Child A
(r)**
3 (12) 9 (45)
Child B 9 (36) 8 (40) 0.30
(0.06–1.50)
2.30 0.130
Child C 13 (52) 3 (15) 0.08
(0.01–0.50)
8.86 0.003*
*Statistical signiﬁcance at P < 0.05, **reference group.
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signiﬁcantly decreased, while INR was signiﬁcantly increased in
Toxoplasma positive compared to Toxoplasma negative chronic
HCV cases, (P = 0.001, 0.04, 0.03, respectively). On the other
hand, there was no association between Toxoplasma serostatus
and levels of bilirubin, ALT, AST, ALP, HB, WBC count and
HCV RNA (P = 0.5, 0.3, 0.3, 0.06, 0.2, 0.6, 0.5, Table 4). When
Child-Pugh scoring system was adopted to assess the prognosis
of liver cirrhosis in chronic HCV group (Table 5), the majority
of Toxoplasma seropositive cases were class C (13/25, 52%)
compared to only 15% of Toxoplasma seronegative cases while
36%, 12% of Toxplasma seropositive cases, in contrast to 40%and 45% of Toxoplasma seronegative cases were class B and A,
respectively, with signiﬁcant statistical difference between Child
C and Child A reference group (OR = 0.08; 95% CI: 0.01–0.5;
P = 0.003).
4. Discussion
There have been few attempts to identify the prevalence of
toxoplasmosis in patients with hepatic ailment, a medical
important point particularly in our region due to the common-
ness of viral hepatitis. Our study declared a statistically signif-
icantly (P = 0.02) higher prevalence of T. gondii IgG antibody in
patients with liver diseases (59/180, 32.8%) versus control
subjects (40/180, 22.2%), a ﬁnding that analogues a Turkish
study [8], showing high Toxoplasma seroprevalence in cirrhotic
patients (68.5%) compared to control (48%) and another
Egyptian study also showing a 65.5% seroprevalence of
T. gondii antibodies in patients with acute and chronic hepatic
disease against a 27% seroprevalence found in controls [17].
However, a Mexican study [18] demonstrated approximate
frequency of anti-T. gondii IgG antibodies in liver disease
patients (13.3%) and controls (10.7%), possibly because of
small study sample size. Yet, levels of anti-T. gondii IgG
antibodies were comparable in our patient and control groups
(P = 0.5), indicating that T. gondii infection is not likely to
virtually engage in the etiology of liver disease in our patients
(data not shown).
The sociodemographic characteristics showed no association
to Toxoplasma seropositivity in patient groups as the protozoan
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transmission. Among clinical data, lymphadenopathy, history of
blood transfusion and reﬂex impairment were signiﬁcantly
higher in seropositive patients (P = 0.01, 0.0003, 0.0003,
respectively). Lymphadenopathy is the most characteristic clin-
ical presentation of toxoplasmosis [10] that accounts for about
15%–20% of unexplained lymphadenopathy cases, especially
those affecting cervical nodes [19]. It may occur at different
times after the initial T. gondii infection, persist, and/or recur
for various times independently of the speciﬁc antiparasitic
treatment [20]. However, ﬁne-needle aspiration cytology is
essential to diagnose Toxoplasma lymphadenitis [21] especially
in immunocompromised patient, as serological analysis can
yield false negative result [19].
Toxoplasma infection can be transmitted through blood
transfusion [22]. The rate of Toxoplasma infection in healthy
blood donors varies in different areas of the world depending
on the rate of infection in the community. In some areas like
Northeast Brazil, North Egypt and North India, more than
50% of blood donors were seropositive for Toxoplasma
infection [23–25]. To prevent transfusion transmitted
toxoplasmosis, at least the patients with a higher risk of
clinical consequences of Toxoplasma infections should receive
T. gondii free blood. The approaches could be maintaining an
inventory of T. gondii IgM negative blood [26] and/or
provision oﬂeucocyte reduced blood components [27].
We noticed that 35.6% of Toxoplasma seropositive patients
(21/59) have reﬂex impairment compared to only 12.4% of
Toxoplasma seronegatives (15/121), a ﬁnding that goes in har-
mony with Alvarado-Esquivel [18]. In human, toxoplasmosis can
cause myalgia and muscle weakness due to myositis [28]. Behan
[29] postulated that an immune disturbance possibly activates
latent infection and induces inﬂammatory myopathy. Recently,
Cuomo [30] reported a case of polymyositis in an
immunocompetent patient attributed to toxoplasmosis. Despite
the possible implication of the host immune response in
pathogenesis of Toxoplasma polymyositis [31], the patient
didn't respond to corticosteroids but to speciﬁc treatment with
pyrimethamine and sulfodiazine.
Noteworthy, chronic HCV patients in the present study as
well as those with related cirrhosis expressed a higher preva-
lence of T. gondii seropositivity (33.3% and 55.6%, respec-
tively) than patients suffering from chronic HBV and related
cirrhosis (11.1% and 20.8%, respectively) with signiﬁcant sta-
tistical difference for each comparison (P = 0.013, 0.006,
respectively). A larger sample size, would have better expressed
the prevalence of the parasite in chronic HBV patients as adult-
onset HBV infections are typically self-limited and cleared in
about 95% of patients [32]. Only about one-third of adults
develop jaundice and hepatitis and less than 1% presents a
fulminant course [33]. In contrast, only a minority (about 30%)
of HCV-infected adults is able to clear the virus spontane-
ously [34].
Moreover, the results in Table 3 shows the higher prevalence
of Toxoplasma seropositivity found in chronic HCV patients
with late stages ﬁbrosis (stages F3 and F4) as compared to early
stages (stages F1 and F2) besides the signiﬁcant P value of
0.0008 when the former was compared to F0 stage. Worth
mentioning, sampling error [35] and inter-and-intra observer
variability [36] are considerable contributing factors [37].
Seropositivity of T. gondii was also found to be signiﬁcantlyincreased with the higher activity of inﬂammation (P = 0.01)
and associated advanced degree and extent of necrosis. It is
possible that Toxoplasma, which is known to cause partial
damage to the liver, may have a turn in the commencement
and clinical course of cirrhosis. T. gondii inﬂuence on the
hepatic disease evolution and vice versa is not clear.
Nevertheless, the observed high vulnerability to T. gondii
infection among hepatic patients demonstrates the existence of
a correlation. This observation is not surprising since cirrhosis
results in immunodeﬁciency state which favors T. gondii
infection.
Immunity to toxoplasmosis is largely T-cell mediated; CD8+
T cells play a major role as effector lymphocytes against the
parasite [38], whereas CD4+ T cells are important to regulate
immune responses to T. gondii [39] and both are known to act
synergistically providing a protective immunity that allows the
survival of the host during chronic infection [40]. IFN-g is
critical for mediating protective immunity to Toxoplasma, and
during chronic infection CD8+ T cells are a major source of
this cytokine, which is essential for controlling parasite
reactivation [41]. Comparably, spontaneous viral clearance of
HBV and HCV infection demands vigorous and sustained
multi-epitope-speciﬁc CD4+ and CD8+ T-cell responses during
the acute phase of infection. In contrast, late, transient, week or
narrowly focused CD4+ and CD8+ T-cell responses depict
chronic infection with both viruses [42,43].
The laboratory parameters in chronic HCV group were
within or slightly altered than normal values, a ﬁnding that
supports the biological role of regulatory CD4+ T cells [44],
though albumin and platelets count were signiﬁcantly lower
and INR was signiﬁcantly higher in Toxoplasma positive
compared to Toxoplasma negative chronic HCV patients
(P = 0.001, 0.04, 0.03, respectively). Several factors, including
parasitic and infectious diseases, may inﬂuence the ﬂuctuation
of serum proteins. Da Silva [45] and Bottari [46] reported
decreased level of serum albumin in experimentally
Toxoplasma infected mice due to liver injury.
Theoretically, any bacterial or protozoal infection can be
associated with thrombocytopenia that is caused by mecha-
nisms such as increased clearance of damaged platelets with
endotoxins, exotoxins, or platelet-activating factor or direct
platelet toxicity caused by the microorganism, immune-
mediated destruction of the platelets, and platelet adherence
to damaged vascular surfaces [47]. Rarely, acquired
toxoplasmosis in an immunocompetent patient may be
associated with severe thrombocytopenia [48], but
thrombocytopenia was noted in congenital toxoplasmosis, in
six of seven parasitologically proved cases [49] and in
experimentally infected rats, following infection with
tachyzoites [50]. The exact pathogenesis is not clear. Of
interest, blood platelets are suggested to have a role in
destroying parasites [51]. In toxoplasmosis, a platelet derived
growth factor isolated from a-granules of platelets, elicited a
human platelet-mediated cytoinhibition of T. gondii intracel-
lular growth in vitro, in absence of antibodies [50]. Its action
against intracellular tachyzoites also includes increased IL-6
secretion that is one of the most potent enhancers of NK cell
production of IL-17, which is essential for generating an
optimal polymorphonuclear response against T. gondii infection
[52,53]. Consequently, possibly thrombocytopenia in hepatic
patients renders them more susceptible to toxoplasmosis.
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Toxoplasma positive-chronic HCV patients, mostly because of
longer prothrombin time (PT). The importance of the last two
ﬁndings gathered is highlighted by the concept of Bonacini [54]
who declared that thrombocytopenia and prolonged PT are
routine test results that predict likelihood of cirrhosis. In
general, the liver, as the site of HBV and HCV infection is
known to be a tolerogenic environment. For example, murine
Kupffer cells constitutively express the immunosuppressive
cytokines IL-10 and transforming growth factor b that are
involved in the generation of a unique cytokine environment
mainly inducing tolerance of liver-inﬁltrating lymphocytes [55].
Child's score, initially termed Child-Turcotte score [56], or
the modiﬁed version termed Child-Pugh score [57] is used to
assess the prognosis of chronic liver disease, mainly
cirrhosis. It includes two continuous variables (bilirubin and
albumin) and three discrete variables (ascites,
encephalopathy, and PT) which were empirically selected
because of their own inﬂuence on the prognosis in this
context [58]. Applying the score assessment to chronic HCV-
related cirrhosis patients in our study obviated that the major-
ity of Toxoplasma seropositive cases were class C (52%)
compared to only 15% of Toxoplasma seronegative patients
while 12% of Toxplasma seropositive cases, opposed to 45% of
Toxoplasma seronegative patients were class A, with signiﬁ-
cant statistical difference between Child C and Child A refer-
ence group (P = 0.003).
Severe lesions due to acute toxoplasmosis have been
noticed in visceral organs such as the liver, lung, and spleen of
mammalian species [59]. In the liver, it causes pathological
changes that headway to hepatomegaly, granuloma, hepatitis,
and necrosis [60]. Moreover, some epidemiological studies
have reported an association of T. gondii infection with liver
cirrhosis [18]. Intravital microscopy imaging studies have
determined that apicomplexan parasites such as T. gondii
invade the liver, gradually move toward the surface of
sinusoidal epithelial cells to the Kupffer cells, ultimately
entering and developing in the cytoplasm of hepatocytes [61].
Experimentally, Atmaca [60] found parasite clusters became
apparent in both hepatocytes and stellate cells 4 and 6 d
after infection and reported that the number of activated
hepatic stellate cells (HSCs); known to play an important
role in the development of ﬁbrosis and its advancement to
cirrhosis [62] was signiﬁcantly higher in the T. gondii
infected group than that in the healthy group. Besides, HCV-
infected hepatocytes release transforming growth factor b
and other proﬁbrogenic factors that differentially modulate
HSC expression of several key genes involved in liver ﬁbrosis
[63] documenting the role of HSCs in HCV-mediated liver
ﬁbrosis.
From the fore mentioned ﬁndings, it is plausible to conclude
that patients suffering from viral hepatitis particularly HCV are
vulnerable to toxoplasmosis as evidenced by Toxoplasma sero-
positivity. Consequent evolution of hepatic pathology and
development of cirrhosis must be considered. More detailed
studies are needed to address this matter particularly in Egypt
wherein one of the highest HCV prevalence in the world exists.
Because the majority of the mortality caused by Toxoplasma is
due to parasite reactivation in immunocompromised patients,
there is an urgent need for development of immunotherapeutic
vaccination approaches to combat this infection in hepatic pa-
tients whom form a risk group for Toxoplasma.Acknowledgments
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